The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 340 participants.

Also called NCT05505994

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 340 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05505994
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05505994. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-28 (actual); primary completion 2024-02-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
Condition
Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Condition
Glucose Metabolism Disorders
Condition
Metabolic Disease
Condition
Endocrine System Diseases
Intervention (Drug)
DWP16001
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
DWP16001 Placebo
Intervention (Drug)
Dapagliflozin Placebo
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct05505994
Content hash
de2830b7e1cf4dd3454c108c6b170fab25e18a54c5fd254dda6326d3cd5fdef0